Currently, six BCR::ABL targeting TKIs are approved by the United States Food and Drug Administration for CML treatment: first-generation TKI Imatinib, second-generation TKIs Dasatinib, Nilotinib, and Bosutinib, and third-generation TKIs Ponatinib and Asciminib. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.